Dunne, Jessica L.
Richardson, Sarah J.
Atkinson, Mark A.
Craig, Maria E.
Dahl-Jørgensen, Knut
Flodström-Tullberg, Malin
Hyöty, Heikki
Insel, Richard A.
Lernmark, Åke
Lloyd, Richard E.
Morgan, Noel G.
Pugliese, Alberto
Funding for this research was provided by:
Diabetes UK (15/0005364)
Medical Research Council (MR/P010695/1)
Swedish Child Diabetes Foundation
South-Eastern Norway Regional Health Authority (Thyroid and Virus Detection and Intervention)
Novo Nordisk Foundation
JDRF (5-CDA-2014-221-A-N)
European Union’s Seventh Framework Programme (261441 PEVNET)
Swedish Research Council
Article History
Received: 21 August 2018
Accepted: 11 December 2018
First Online: 23 January 2019
Duality of interest
: HH is a shareholder and member of the Board of Vactech Ltd., which develops picornavirus vaccines. RAI, HH and MF-T serve on the scientific advisory board of Provention Bio Inc., which is developing an enterovirus vaccine. RAI has stock options in Provention Bio Inc.